$50,000 of HUMACYTE lobbying was just disclosed, from Q2 of 2026, in a new Lobbying Disclosure Act filing.
This included lobbying on issues like:
"Issues related to Medicare reimbursement for biological products. Issues related to Medicare reimbursement for biological products. Issues related to supporting access to biologic products to treat warfighters. Supporting funding for procurement of biologic products to treat post-combat trauma. Issues related to supporting access to biologic products to treat warfighters."
You can find more data on corporate lobbying on Quiver Quantitative.
HUMA Insider Trading Activity
HUMA insiders have traded $HUMA stock on the open market 4 times in the past 6 months. Of those trades, 2 have been purchases and 2 have been sales.
Here’s a breakdown of recent trading of $HUMA stock by insiders over the last 6 months:
- KATHLEEN SEBELIUS purchased 56,818 shares for an estimated $49,999
- DALE A. SANDER (CFO and Chief Corp. Dev. Off) sold 45,887 shares for an estimated $41,146
- SHAMIK J PARIKH (Chief Medical Officer) sold 45,887 shares for an estimated $41,146
- MICHAEL T. CONSTANTINO purchased 11,000 shares for an estimated $9,839
To track insider transactions, check out Quiver Quantitative's insider trading dashboard. You can access data on insider stock transactions through the Quiver Quantitative API insider transaction endpoint.
HUMA Hedge Fund Activity
We have seen 80 institutional investors add shares of HUMA stock to their portfolio, and 46 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- ANTIPODES PARTNERS LTD added 5,712,102 shares (+49039.3%) to their portfolio in Q1 2026, for an estimated $3,465,532
- MILLENNIUM MANAGEMENT LLC removed 2,523,836 shares (-95.9%) from their portfolio in Q1 2026, for an estimated $1,531,211
- MORGAN STANLEY removed 2,318,685 shares (-92.5%) from their portfolio in Q1 2026, for an estimated $1,406,746
- AQR CAPITAL MANAGEMENT LLC added 1,890,867 shares (+5590.3%) to their portfolio in Q1 2026, for an estimated $1,147,189
- CITADEL ADVISORS LLC removed 1,566,431 shares (-100.0%) from their portfolio in Q1 2026, for an estimated $950,353
- TWO SIGMA INVESTMENTS, LP removed 1,313,931 shares (-88.1%) from their portfolio in Q1 2026, for an estimated $797,161
- BNP PARIBAS FINANCIAL MARKETS removed 1,061,702 shares (-96.4%) from their portfolio in Q1 2026, for an estimated $644,134
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard. You can access data on hedge funds moves and 13F filings through the Quiver Quantitative API 13F endpoint.
HUMA Analyst Ratings
Wall Street analysts have issued reports on $HUMA in the last several months. We have seen 1 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- BTIG issued a "Buy" rating on 02/09/2026
To track analyst ratings and price targets for HUMA, check out Quiver Quantitative's $HUMA forecast page.
HUMA Price Targets
Multiple analysts have issued price targets for $HUMA recently. We have seen 7 analysts offer price targets for $HUMA in the last 6 months, with a median target of $2.0.
Here are some recent targets:
- Joshua Jennings from TD Cowen set a target price of $1.25 on 06/17/2026
- Ryan Zimmerman from BTIG set a target price of $2.0 on 06/16/2026
- Swayampakula Ramakanth from HC Wainwright & Co. set a target price of $4.0 on 06/11/2026
- Bruce D. Jackson from Benchmark set a target price of $2.0 on 06/01/2026
- Jason Kolbert from D. Boral Capital set a target price of $25.0 on 04/28/2026
- Matt Miksic from Barclays set a target price of $1.5 on 04/08/2026
- Allison Bratzel from Piper Sandler set a target price of $1.0 on 03/30/2026
This article is not financial advice. See Quiver Quantitative's disclaimers for more information.
